Breast cancer patients prefer knowing costs prior to starting treatment

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Even when they had good health insurance coverage, women with breast cancer reported having financial worries related to their care, and the vast majority said they preferred to know about treatment costs at the time of diagnosis.

The findings from a study by Duke Cancer Institute researchers highlight the importance of considering medical costs as women face breast cancer treatment decisions.

The vast majority of women—eight out of 10—said they preferred knowing the costs of treatment prior to embarking on cancer care. And 40 percent preferred that doctors consider costs when making treatment recommendations.

In the study, the Duke team surveyed more than 750 women after breast cancer from the Army of Women and Sisters Network, national organizations of women after breast cancer. All were women with a median age of about 50. Most had either private health insurance or Medicare, and had annual household income of more than $74,000.

Even within this group—financially better off than many cancer patients—nearly 16 percent reported significant to catastrophic financial burden.

Median reported out-of-pocket costs were $3,500, although 5 percent of women faced out-of-pocket costs over $30,000.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login